antibody-drug conjugates

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+

Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…

by Timos Papagatsias

Cell_Gene_Therapy

Cell and Gene Therapy Today—November 27, 2025

This week's Cell and Gene therapy update covers major regulatory approvals,…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: NEOK Bio $75M Series A

Lucid Diligence Brief: NEOK Bio $75M Series A Professional audiences only. Not…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: GSK and Syndivia preclinical ADC in mCRPC

Lucid Diligence Brief: GSK and Syndivia preclinical ADC in mCRPC Professional…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Takeda and Innovent global oncology partnership

Lucid Diligence Brief: Takeda and Innovent global oncology partnership…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040

Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040 Professional…

by Timos Papagatsias

AACR 2025_Preview_by_LucidQuest

AACR 2025 Preview: Key Cancer Research Highlights to Watch

AACR 2025 at a glance As AACR 2025 nears, LucidQuest spotlights the…

by LucidQuest

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.